How big is the hypercholesterolemia market today, and what are its future growth expectations?
The hypercholesterolemia market size has grown rapidly in recent years. It will grow from $16.30 billion in 2024 to $18.66 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to rising health campaigns, increased research and development, rising focus on preventive healthcare, expansion of preventive health screenings and lifestyle modifications.
The hypercholesterolemia market size is expected to see rapid growth in the next few years. It will grow to $31.70 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to improved diagnosis and screening, government initiatives and health policies, growing prevalence of risk factors, growing availability of over-the-counter (OTC) cholesterol-lowering products and increased awareness of cholesterol risks. Major trends in the forecast period include advanced lipid profiling, robotic-assisted surgeries, nanotechnology in drug delivery, telemedicine platforms and lipoprotein targeting.
Get Your Free Sample of The Global Hypercholesterolemia Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21207&type=smp
What have been the primary factors driving the hypercholesterolemia market’s growth?
Increasing cardiovascular diseases is expected to propel the growth of the hypercholesterolemia market going forward. Cardiovascular diseases (CVDs) refer to a group of disorders that affect the heart and blood vessels. The increase in cardiovascular diseases is due to unhealthy diets, physical inactivity, rising obesity rates, chronic stress, aging populations, and the prevalence of conditions such as hypertension and diabetes. Hypercholesterolemia treatment supports cardiovascular disease patients by lowering LDL cholesterol levels, reducing arterial plaque buildup, improving blood flow, and decreasing the risk of heart attacks, strokes, and other cardiovascular complications. For instance, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, each year, approximately 805,000 people in the United States experience a heart attack, of these, 605,000 are first-time incidents, while 200,000 occur in individuals with a history of previous heart attacks. Therefore, the increasing cardiovascular diseases are expected to drive the growth of the hypercholesterolemia market.
What are the key segments within the hypercholesterolemia market?
The hypercholesterolemia market covered in this report is segmented –
1) By Disease Type: Genetic, Acquired
2) By Treatment: Statins, Bile Acid Resins, Niacin, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Other Treatments
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others Distribution Channel
5) By End User: Hospitals, Specialty Clinics, Home Healthcare, Others End Users
Subsegments:
1) By Genetic: Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
2) By Acquired: Primary Hypercholesterolemia, Secondary Hypercholesterolemia
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/hypercholesterolemia-global-market-report
Which key players are shaping the hypercholesterolemia market?
Major companies operating in the hypercholesterolemia market are Pfizer Inc., Merck & Co Inc., Abbvie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Viatris Inc., Aegerion Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Ionis Pharmaceuticals Inc., Melinta Therapeutics Inc., NewAmsterdam Pharma N.V., HDL Therapeutics Inc.
How will emerging trends drive the hypercholesterolemia market throughout the forecast period?
Major companies operating in the hypercholesterolemia market are developing innovative products, such as a triple-combination drug, to enhance treatment efficacy and patient compliance. A triple-combination drug refers to a pharmaceutical formulation that combines three active ingredients into a single dosage form, such as a tablet or capsule. For instance, in February 2025, Celltrion Pharm, Inc., a South Korea-based pharmaceutical company, launched Amrozet Tablet, a hypertension-hyperlipidemia drug. This medication combines three active ingredients such as amlodipine, a calcium channel blocker for hypertension, rosuvastatin, a statin for lowering cholesterol and ezetimibe, which helps reduce cholesterol absorption in the intestines. The drug is available in four dosage combinations that include 5/5/10 mg, 5/10/10 mg, 10/5/10 mg, and 10/10/10 mg. It is indicated for hypertension and myocardial ischemia under amlodipine and primary hypercholesterolemia under the rosuvastatin-ezetimibe combination. It is also used to relieve chronic stable angina (chest pain) or vasospastic angina and to lower the risk of hospitalization for angina and heart surgery in patients with documented coronary artery disease.
How do regional factors impact the hypercholesterolemia market, and which region is the largest contributor?
North America was the largest region in the hypercholesterolemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hypercholesterolemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Hypercholesterolemia Market Report 2025 Offer?
The hypercholesterolemia market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Hypercholesterolemia refers to an abnormally high level of cholesterol in the blood, particularly low-density lipoprotein (LDL) cholesterol, which increases the risk of atherosclerosis and cardiovascular diseases such as heart attacks and strokes. It is often influenced by genetic factors, poor diet, lack of physical activity, and underlying health conditions like diabetes or hypothyroidism.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21207
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
